Medical progress is steadily increasing life expectancy for cancer patients. A study by VAMED of some 1,000 cancer patients in Austria shows that rehabilitation is improving their quality of life. Cases of depression fell by half after oncological rehabilitation, according to the study, carried out at VAMED’s rehabilitation center in St. Veit, Austria. Anxiety about a possible recurrence of cancer fell by a similar amount. Fresenius Vamed operates 15 rehabilitation centers in Europe.
Fresenius Helios is celebrating the 40th anniversary of the HELIOS ENDO Hospital in Hamburg. This specialist center for bone, joint and spinal surgery treats some 7,000 patients annually. More than 140,000 joint implant and replacement procedures have been carried out at the hospital since its opening in 1976. Over €100 million has been invested in the hospital's modernization in recent years, and a new outpatient surgical department is scheduled to open in mid-2016.
Fresenius Helios has started expanding the HELIOS Amper Hospital in Dachau, near Munich. Within two years a new, multi-story extension will be completed. The existing building that houses the patient wards will then be completely renovated. When all the work is finished in four years, the hospital will have about 100 additional beds. The total investment is about €55 million.
Fresenius Kabi has nearly doubled production capacity at its infusion solutions plant in the Spanish town of Vilassar de Dalt, near Barcelona. The investment volume for the expansion is about €20 million. The Vilassar de Dalt plant produces primarily for the European market, and has about 140 employees.
Dexmedetomidine Hydrochloride Injection, a sedative, further expands the company's anesthesia portfolio.
Fresenius Helios has presented the plan for its new main building at HELIOS Hospital Dr. Horst Schmidt in the German city of Wiesbaden. The seven-story structure, with total floor space of almost 100,000 square meters (more than 1 million square feet), will be built on an open site near the existing hospital building. Patients’ waiting times and the distances they need to cover will be significantly reduced in the new building, which will have 22 operating rooms and more than 900 beds. Construction is scheduled to start next spring, with completion in 2020. Building costs are estimated at around €200 million.
Fresenius Medical Care has opened its China Design Center, in Caohejing Hi-Tech Park in Shanghai. The new facility represents a ramping-up of research and development activities outside of Europe and the United States, and underscores Fresenius Medical Care’s commitment to making its world-leading dialysis treatments and technologies more widely available to patients in China and other emerging markets. In addition to developing a deeper insight into the needs of these markets, the company aims to provide even more innovative and cost-effective solutions for treating kidney disease.
HELIOS Hospital Dr. Horst Schmidt, in the German city of Wiesbaden, will begin training about 160 students annually in nursing and other patient care occupations. The internal continuing education program for all employees now includes more than 2,000 different courses. HELIOS has invested about €3 million in new facilities for the training center, which will include seven modern teaching rooms, practice rooms, and a library.
VAMED-KMB has won the EFQM Excellence Award in the category “Adding Value for Customer” for its technical operations management of Vienna General Hospital. Awarded by the European Foundation for Quality Management, the prize is considered to be Europe’s most prestigious, with the most exacting standards. VAMED-KMB had already won the EFQM Excellence Award three times in various categories over the previous six years. A subsidiary of VAMED AG, VAMED-KMB has been responsible for the technical operations of of Vienna General Hospital since its construction more than 30 years ago. With more than 2,000 beds, the hospital is one of Europe’s biggest.
The cornerstone for the modernization of University Hospital Schleswig-Holstein was laid today in Lübeck, Germany. VAMED and its consortium partner BAM will construct new buildings and renovate existing ones in a €520 million project, with completion scheduled for 2021. In addition, the consortium will provide technical management services until 2044. The total contract has a volume of approximately €1.7 billion.
Moxifloxacin injection further expands the Fresenius Kabi anti-infective portfolio. It is available in the company's proprietary Freeflex® bag.
Cisatracurium Besylate Injection, a neuromuscular blocker, further expands Fresenius Kabi's anesthesia portfolio. Now available in three presentations.
Glucagon injection expands Fresenius Kabi's U.S. critical care portfolio and is sold in 10-packs of 1mg vials.
Argatroban injection expands Kabi's anticoagulant product portfolio. Now available as a 250mg/2.5mL presentation in a single dose vial.
Annual Report 2014 (PDF, 3.04 MB)
Fresenius "At a Glance" (PDF, 167 KB)
Book "100 Years of Fresenius" (PDF, 6.25 MB)
Fresenius Factsheet Q3 2015 (PDF, 740 KB)
Fresenius Medical Care "Profile" (PDF, 266 KB)
Fresenius Medical Care Magazine "Movement" (PDF, 4.30 MB)
Social Media Guidelines (PDF, 1.97 MB)
Investor Relations General Presentation (PDF, 1.09 MB)